Nucleases in homologous recombination as targets for cancer
therapy

J 2014

Nucleases in homologous recombination as targets for cancer therapy

BARTOŠOVÁ, Zdenka and Lumír KREJČÍ

Basic information

Original name

Nucleases in homologous recombination as targets for cancer therapy

Name in Czech

Nukleázy v homologické rekombinaci jako cíle pro léčbu rakoviny

Authors

BARTOŠOVÁ, Zdenka (703 Slovakia, belonging to the institution) and Lumír KREJČÍ (203 Czech Republic, guarantor, belonging to the institution)

Edition

FEBS Letters, Amsterdam, Elsevier Science, 2014, 0014-5793

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

Genetics and molecular biology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.169

RIV identification code

RIV/00216224:14110/14:00073831

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.febslet.2014.06.010

UT WoS

000339535200013

Keywords (in Czech)

Genmická integrita, Homologická rekombinace, Nukleáza, Inhibitor, Léčba rakoviny

Keywords in English

Genomic integrity; Homologous recombination; Nuclease; Inhibitor; Cancer therapy

Abstract

V originále

Genomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous recombination and the role of several nucleases and other recombination factors as suitable targets for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of specific genetic abnormalities of cancer cells that are not present in normal cells and that result in cancer cell lethality. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Links

GAP207/12/2323, research and development project

Name: Endonuleazová a translokázová aktivita v restričních-modifikáčních komplexéch typu I

Investor: Czech Science Foundation

GA13-26629S, research and development project

Name: SUMO a stability genomu

Investor: Czech Science Foundation

Citovat

BARTOŠOVÁ, Zdenka and Lumír KREJČÍ. Nucleases in homologous recombination as targets for cancer therapy. FEBS Letters. Amsterdam: Elsevier Science, 2014, vol. 588, No 15, p. 2446-2456. ISSN 0014-5793. Available from: https://dx.doi.org/10.1016/j.febslet.2014.06.010.

@article{1196972,
   author = {Bartošová, Zdenka and Krejčí, Lumír},
   article_location = {Amsterdam},
   article_number = {15},
   doi = {http://dx.doi.org/10.1016/j.febslet.2014.06.010},
   keywords = {Genomic integrity; Homologous recombination; Nuclease; Inhibitor; Cancer therapy},
   language = {eng},
   issn = {0014-5793},
   journal = {FEBS Letters},
   title = {Nucleases in homologous recombination as targets for cancer therapy},
   volume = {588},
   year = {2014}
}

TY  - JOUR
ID  - 1196972
AU  - Bartošová, Zdenka - Krejčí, Lumír
PY  - 2014
TI  - Nucleases in homologous recombination as targets for cancer therapy
JF  - FEBS Letters
VL  - 588
IS  - 15
SP  - 2446-2456
EP  - 2446-2456
PB  - Elsevier Science
SN  - 00145793
KW  - Genomic integrity
KW  - Homologous recombination
KW  - Nuclease
KW  - Inhibitor
KW  - Cancer therapy
N2  - Genomic DNA is constantly challenged from endogenous as well as exogenous sources. The DNA damage response (DDR) mechanism has evolved to combat these challenges and ensure genomic integrity. In this review, we will focus on repair of DNA double-strand breaks (DSB) by homologous recombination and the role of several nucleases and other recombination factors as suitable targets for cancer therapy. Their inactivation as well as overexpression have been shown to sensitize cancer cells by increasing toxicity to DNA-damaging agents and radiation or to be responsible for resistance of cancer cells. These factors can also be used in targeted cancer therapy by taking advantage of specific genetic abnormalities of cancer cells that are not present in normal cells and that result in cancer cell lethality. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
ER  -

BARTOŠOVÁ, Zdenka and Lumír KREJČÍ. Nucleases in homologous recombination as targets for cancer therapy. \textit{FEBS Letters}. Amsterdam: Elsevier Science, 2014, vol.~588, No~15, p.~2446-2456. ISSN~0014-5793. Available from: https://dx.doi.org/10.1016/j.febslet.2014.06.010.

Detailed Information on Publication Record